Licensing status

Publication and contact information


Vascular catheters modified with polysulfobetaine to prevent thrombus formation and microbial attachment

Polysulfobetaine surface modification of vascular catheters could help prevent catheter-associated thrombosis and infection. Nonleaching polysulfobetaine was attached to the inner surface of commercially available, peripherally inserted central catheters. In a canine model of thrombosis, the polysulfobetaine-modified catheter showed a 99% decrease in thrombus formation compared with an unmodified catheter. The modified catheter also showed 97%-99.9% lower adhesion of 5 tested microbes and 97% less biofilm formation with Staphylococcus aureus than the unmodified catheter.
The Semprus BioSciences Corp. unit of Teleflex Inc. markets the polysulfobetaine-modified catheter in the EU, and the product is under FDA review.

SciBX 5(40); doi:10.1038/scibx.2012.1062
Published online Oct. 11, 2012

Covered by multiple issued and pending patents; licensing status undisclosed

Smith, R.S. et al. Sci. Transl. Med.; published online Sept. 26, 2012;
Contact: Christopher Loose, Semprus BioSciences Corp., Cambridge, Mass.